biotech · Immune Thrombocytopenia
Principia Biopharma
Principia Biopharma, a Sanofi Company
Principia Biopharma, a is a biotech organization headquartered in WILMINGTON, US. Primary therapeutic focus areas include Immune Thrombocytopenia. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 pate
South San Francisco, USA HQ
2008 Founded
16 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- South San Francisco, USA
- Founded
- 2008
- Employees
- 16
- Programs
- 1
- Drugs
- 1
- Patents
- 0
Rilzabrutinib
Phase 3 · small molecule · Immune Thrombocytopenia
Rilzabrutinib for Immune Thrombocytopenia is a Phase 3 program (small_molecule) at Principia Biopharma, a Sanofi Company with 1 ClinicalTrials.gov record(s).
Internal code EFC17093
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Principia Biopharma, a Sanofi Company
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Immune Thrombocytopenia
- Status
- active
- Trials
- 1